Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Int J Infect Dis
; 122: 585-592, 2022 Sep.
Article
in En
| MEDLINE
| ID: mdl-35788416
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Clinical_trials
/
Etiology_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Int J Infect Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2022
Document type:
Article
Country of publication:
Canadá